Log In / Register
Sucampo has aquired Vtesse
5 July, 2017
Sucampo Pharmaceuticals Inc., a global biopharmaceutical company has aquired Vtesse, rare disease company.
Sucampo will accelerate the development and potential commercialization of VTS-270 (2-hydroxypropyl-beta-cyclodextrin with a defined compositional fingerprint), now in a pivotal clinical trial for the treatment of Niemann Pick type C disease. The Vtesse team joined Sucampo to continue supporting the advancement of VTS-270.
BACK TO NEWS